Paper29527331
Targeting oncogenic Myc as a strategy for cancer treatment.
Chen H and 2 others. Signal Transduct Target Ther, 2018. Cited by 665 papers, by iCite.
Cite this record
ConductScience Library. Targeting oncogenic Myc as a strategy for cancer treatment. Papers, record 29527331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29527331
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References97
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21964340 | Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. | Nature | 2011 | https://conductscience.org/library/papers/21964340 | PubMed |
| 2 | 7824278 | Phosphorylation of a specific cdk site in E2F-1 affects its electrophoretic mobility and promotes pRB-binding in vitro. | Oncogene | 1995 | https://conductscience.org/library/papers/7824278 | PubMed |
| 3 | 20884625 | Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. | Clin Cancer Res | 2010 | https://conductscience.org/library/papers/20884625 | PubMed |
| 4 | 22982363 | Dynamic phosphorylation patterns of RNA polymerase II CTD during transcription. | Biochim Biophys Acta | 2013 | https://conductscience.org/library/papers/22982363 | PubMed |
| 5 | 9824157 | Design and properties of a Myc derivative that efficiently homodimerizes. | Oncogene | 1998 | https://conductscience.org/library/papers/9824157 | PubMed |
| 6 | 17015432 | Control of cellular senescence by CPEB. | Genes Dev | 2006 | https://conductscience.org/library/papers/17015432 | PubMed |
| 7 | 16064138 | Transcriptional regulation and transformation by Myc proteins. | Nat Rev Mol Cell Biol | 2005 | https://conductscience.org/library/papers/16064138 | PubMed |
| 8 | 26528759 | Myc promotes glutaminolysis in human neuroblastoma through direct activation of glutaminase 2. | Oncotarget | 2015 | https://conductscience.org/library/papers/26528759 | PubMed |
| 9 | 26390243 | Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. | Nat Med | 2015 | https://conductscience.org/library/papers/26390243 | PubMed |
| 10 | 26186940 | Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. | Blood | 2015 | https://conductscience.org/library/papers/26186940 | PubMed |
| 11 | 16935001 | Conditional transgenic models define how MYC initiates and maintains tumorigenesis. | Semin Cancer Biol | 2006 | https://conductscience.org/library/papers/16935001 | PubMed |
| 12 | 23021215 | Transcriptional amplification in tumor cells with elevated c-Myc. | Cell | 2012 | https://conductscience.org/library/papers/23021215 | PubMed |
| 13 | 28174256 | A Time for MYC: Metabolism and Therapy. | Cold Spring Harb Symp Quant Biol | 2016 | https://conductscience.org/library/papers/28174256 | PubMed |
| 14 | 17606868 | Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. | J Cell Biol | 2007 | https://conductscience.org/library/papers/17606868 | PubMed |
| 15 | 15930260 | Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy. | Cancer Res | 2005 | https://conductscience.org/library/papers/15930260 | PubMed |
| 16 | 1350857 | The bromodomain: a conserved sequence found in human, Drosophila and yeast proteins. | Nucleic Acids Res | 1992 | https://conductscience.org/library/papers/1350857 | PubMed |
| 17 | 25632068 | The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC. | Ann Oncol | 2015 | https://conductscience.org/library/papers/25632068 | PubMed |
| 18 | 9552388 | The family of polo-like kinases. | Prog Cell Cycle Res | 1996 | https://conductscience.org/library/papers/9552388 | PubMed |
| 19 | 18177721 | The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. | Cell Metab | 2008 | https://conductscience.org/library/papers/18177721 | PubMed |
| 20 | 22464321 | MYC on the path to cancer. | Cell | 2012 | https://conductscience.org/library/papers/22464321 | PubMed |
Cited by496
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 665 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42966755 | Conformational heterogeneity: a fundamental mechanism of adaptive phenotypic plasticity and therapeutic resistance. | Br J Cancer | 2026 | https://conductscience.org/library/papers/42966755 | PubMed |
| 42934665 | From motion to molecules: exercise-triggered large EVs suppress oncogenic signaling in lung adenocarcinoma cells - an in vitro pilot study. | Cancer Cell Int | 2026 | https://conductscience.org/library/papers/42934665 | PubMed |
| 42540626 | Apatinib resistance mediated by IRF9 nuclear translocation in head and neck squamous cell carcinoma. | iScience | 2026 | https://conductscience.org/library/papers/42540626 | PubMed |
| 42536269 | Carbohydrates metabolic reprogramming and tumor microenvironment in pancreatic cancer: targeting pathways. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42536269 | PubMed |
| 42490795 | Transcription Factor MAX Regulates Liver Cancer Cell Growth, Migration, Invasion, and Epithelial-Mesenchymal Transition by Promoting SF3A3 Expression. | World J Oncol | 2026 | https://conductscience.org/library/papers/42490795 | PubMed |
| 42426296 | Paediatric therapeutic development workshop on medulloblastoma. | Br J Cancer | 2026 | https://conductscience.org/library/papers/42426296 | PubMed |
| 42362505 | EphB4 inhibition defines a druggable synthetic-lethal vulnerability in MYC-driven triple-negative breast cancer. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/42362505 | PubMed |
| 42346864 | c-Myc-Induced Therapy Resistance in Leukemia: Mechanisms and Emerging Therapeutic Opportunities. | Med Sci (Basel) | 2026 | https://conductscience.org/library/papers/42346864 | PubMed |
| 42326536 | Single-cell gain-of-function mapping reveals latent regulatory programs governing CD8+ T cell fate. | Res Sq | 2026 | https://conductscience.org/library/papers/42326536 | PubMed |
| 42278393 | MYC_V1-Related Genes Affect Gastric Cancer Proliferation by Regulating Energy Metabolism and Analysis of Therapeutic Targets. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42278393 | PubMed |
| 42247584 | No Time to Fold: Intrinsically Disordered Microproteins in Action. | Biochemistry | 2026 | https://conductscience.org/library/papers/42247584 | PubMed |
| 42224600 | Crotonylation impedes c-Myc oncogenic activity. | Proc Natl Acad Sci U S A | 2026 | https://conductscience.org/library/papers/42224600 | PubMed |
| 42199344 | Coconut oil/lauric acid-based nanodrug formulation: a multifunctional platform for enhancing cancer therapy and mitigating toxicity. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42199344 | PubMed |
| 42140671 | MYC serine 62 phosphorylation promotes its association with DNA double-strand breaks to facilitate repair and cell survival under genotoxic stress. | Genes Dev | 2026 | https://conductscience.org/library/papers/42140671 | PubMed |
| 42094195 | Treatment outcomes and next-generation sequencing of a rare malignancy - urachal carcinoma: case report and literature review. | Front Oncol | 2026 | https://conductscience.org/library/papers/42094195 | PubMed |
| 42072056 | Alpha-Lipoic Acid Inhibits IFN-γ-Induced PD-L1 Expression in Prostate Cancer Cells and Enhances T-Cell-Mediated Anti-Tumor Cytotoxicity. | Antioxidants (Basel) | 2026 | https://conductscience.org/library/papers/42072056 | PubMed |
| 41972179 | MIZ-1 controls transcriptional programs required for BCR signaling, actin dynamics, and naïve B cell survival. | Front Immunol | 2026 | https://conductscience.org/library/papers/41972179 | PubMed |
| 41964004 | KRAS and MYC synergistic inhibition: a powerful strategy targeting KRAS-mutant cancers. | Mol Cancer | 2026 | https://conductscience.org/library/papers/41964004 | PubMed |
| 41945431 | Targeted degradation of c-Myc through the midnolin-proteasome pathway. | Proc Natl Acad Sci U S A | 2026 | https://conductscience.org/library/papers/41945431 | PubMed |
| 41930322 | Nanobody-Mediated c-MYC Degradation Inhibits Tumor Cell Progression. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/41930322 | PubMed |
Genes33
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29527331
GET https://conductscience.org/api/papers/v1/29527331/references?page=2